VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
01 mars 2021 08h00 HE
|
VYNE Therapeutics Inc.
Announces promising preclinical data on FMX114 Phase 2a clinical study in AD expected to begin in 3Q 2021 with top-line results by year end Further details on FMX114, including clinical...
VYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4
23 févr. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the year ended...
VYNE Therapeutics Announces Reverse Stock Split
11 févr. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of...
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
01 févr. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
29 janv. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct...
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
26 janv. 2021 07h59 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), today announced that it has entered into definitive agreements with...
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company
21 janv. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel...
VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week
05 janv. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate...
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
17 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing...
VYNE Therapeutics Added to Nasdaq Biotechnology Index
16 déc. 2020 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary...